Evidence mapPaperPMID 19549927Full record

ReviewPharmacological reviews2009

Extracellular matrix molecules: potential targets in pharmacotherapy.

Hannu Järveläinen, Annele Sainio, Markku Koulu, Thomas N Wight, Risto Penttinen

Open access · bronzeAbstract readReview
In one paragraph

Review in Pharmacological reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 241 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
241citing papers in PubMed, 2 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

241 citing papers in PubMed, 2 syntheses or guidelines pooled it, 543 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Physiology (Bethesda, Md.) · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Rethinking Matrigel: The Complex Journey to Matrix Alternatives in Organoid Culture.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  11. Review
  12. Biomimetic Cell Membrane-Coated Scaffolds for Enhanced Tissue Regeneration.Advanced materials (Deerfield Beach, Fla.) · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

181 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Hannu JärveläinenDepartment of Medicine, Turku University Hospital, Kiinamyllynkatu 4-8, FI-20520 Turku, Finland. hannu.jarvelainen@utu.fi
Annele Sainio
Markku Koulu
Thomas N Wight
Risto Penttinen
Benaroya Research InstituteUniversity of Washington · USVirginia Mason Medical Center · US

Funding

VASCULAR CELL GROWTH AND MATRICELLULAR PROTEINSP01HL018645 · UNIVERSITY OF WASHINGTON · 1985 to 2004
$11.2M
Humna ES Cells for Cardiac Tissue EngineeringR24HL064387 · UNIVERSITY OF WASHINGTON · 2000 to 2004
$9.4M
NHLBI NIH HHS HL18645NHLBI NIH HHS P01 HL018645NHLBI NIH HHS R24 HL064387NHLBI NIH HHS R24-HL64387-06A1
6 · The paper itself

Abstract

The extracellular matrix (ECM) consists of numerous macromolecules classified traditionally into collagens, elastin, and microfibrillar proteins, proteoglycans including hyaluronan, and noncollagenous glycoproteins. In addition to being necessary structural components, ECM molecules exhibit important functional roles in the control of key cellular events such as adhesion, migration, proliferation, differentiation, and survival. Any structural inherited or acquired defect and/or metabolic disturbance in the ECM may cause cellular and tissue alterations that can lead to the development or progression of disease. Consequently, ECM molecules are important targets for pharmacotherapy. Specific agents that prevent the excess accumulation of ECM molecules in the vascular system, liver, kidney, skin, and lung; alternatively, agents that inhibit the degradation of the ECM in degenerative diseases such as osteoarthritis would be clinically beneficial. Unfortunately, until recently, the ECM in drug discovery has been largely ignored. However, several of today's drugs that act on various primary targets affect the ECM as a byproduct of the drugs' actions, and this activity may in part be beneficial to the drugs' disease-modifying properties. In the future, agents and compounds targeting directly the ECM will significantly advance the treatment of various human diseases, even those for which efficient therapies are not yet available.

Indexed as

AnimalsDrug Delivery SystemsExtracellular Matrix ProteinsHumansExtracellular Matrix Proteins

Identifiers

PMID19549927
PMCPMC2830117
OpenAlexW2158287992

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.